Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients

Oncotarget

Volumn 6, Issue 10, 2015, Pages 8261-8270

  Napolitano, Maria ^a   D'Alterio, Crescenzo ^a   Cardone, Eleonora ^a   Trotta, Anna Maria ^a   Pecori, Biagio ^a   Rega, Daniela ^a   Pace, Ugo ^a   Scala, Dario ^a   Scognamiglio, Giosuè ^a   Tatangelo, Fabiana ^a   Cacciapuoti, Carmela ^a   Pacelli, Roberto ^b   Delrio, Paolo ^a   Scala, Stefania ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

MDSC; Radiotherapy; Rectal cancer; Treg

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD33 ANTIGEN; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; PDCD1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRANULOCYTIC MYELOID DERIVED SUPPRESSOR CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MIDDLE AGED; MONOCYTIC MYELOID DERIVED SUPPRESSOR CELL; PILOT STUDY; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PREOPERATIVE RADIOTHERAPY; RADIATION RESPONSE; RECTUM CANCER; RECTUM SURGERY; REGULATORY T LYMPHOCYTE; SHORT COURSE PREOPERATIVE RADIOTHERAPY; SUPPRESSOR CELL; TOTAL MESORECTAL EXCISION; TREATMENT RESPONSE; VERY ELDERLY; ADJUVANT RADIOTHERAPY; BONE MARROW CELL; IMMUNOLOGY; NEOADJUVANT THERAPY; PATHOLOGY; RECTAL NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELOID CELLS; NEOADJUVANT THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 84928389008     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3014     Document Type: Article

References (43)

1. Hellevik T, Martinez-Zubiaurre I. Radiotherapy and the tumor stroma: the importance of dose and fractionation. Front Oncol. 2014; 4:1.
2. De Maria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol. 2012; 26:2-153.
3. Formenti SC, Demaria SJ. Combining radiotherapy and cancer immunotherapy: a paradigm shift. Natl Cancer Inst. 2013; 105:256-265.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012; 62:10-29.
5. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351:1731-40.
6. Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet. 2005; 365:153-165.
7. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006; 8:1215-23.
8. Swedish rectal cancer trial: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997; 336:980-87.
9. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001; 8:638-46.
10. Radu C, Berglund A, Påhlman L, Glimelius B. Shortcourse preoperative radiotherapy with delayed surgery in rectal cancer-a retrospective study. Radiother Oncol. 2008; 87:343-49.
11. Pettersson D, Holm T, Iversen H, Blomqvist L, Glimelius B, Martling A. Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg. 2012; 13:577-83.
12. Nilsson PJ, van Etten B, Hospers GA, Påhlman L, van de Velde CJ, Beets-Tan RG, Blomqvist L, Beukema JC, Kapiteijn E, Marijnen CA, Nagtegaal ID, Wiggers T, Glimelius B. Short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer-the RAPIDO trial. BMC Cancer. 2013; 13:279.
13. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140:883-99.
14. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pagès F, Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, th17) in patients with colorectal cancer. Cancer Res. 2011; 71:1263-71.
15. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012; 12:253-68.
16. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9:162-74.
17. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010; 70:68-77.
18. Shevach EM. Mechanisms of FOXP3+ T regulatory cellmediated suppression. Immunity. 2009; 30:636-45.
19. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer. 2007; 7:880-87.
20. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T. FOXP3+ CD25+ CD4+ natural regulatory T cells in dominant selftolerance and autoimmune disease Immunol Rev. 2006; 212:8-2.
21. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009; 58:49-59.
22. Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, O'Donoghue DP, Moriarty M, Fennelly D, Sheahan K. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005; 47:141-6.
23. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12:252-64.
24. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 2010; Mar 1;120:694-705.
25. Caiado F, Carvalho T, Rosa I, Remédio L, Costa A, Matos J, Heissig B, Yagita H, Hattori K, da Silva JP, Fidalgo P, Pereira AD, Dias S. Bone Marrow-Derived CD11b + Jagged 2 + Cells Promote Epithelial-to-Mesenchymal Transition and Metastasization in Colorectal Cancer. Cancer Res. 2013; 73:4233-46.
26. Sun HL, Zhou X, Xue YF, Wang K, Shen YF, Mao JJ, Guo HF, Miao ZN. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J Gastroenterol. 2012; 18:3303-09.
27. Betge J, Kornprat P, Pollheimer MJ, Lindtner RA, Schlemmer A, Rehak P, Vieth M, Langner C. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer. Ann Surg Oncol. 2012; 19:3706-12.
28. Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigenspecific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol. 2009; 21:1065-1077.
29. Deng L, Liang H, Burnette B, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014; 124:687-95.
30. Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment-tumorigenesis and therapy. Nat Rev Cancer. 2005; 5:867-75.
31. Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol. 2009; 85:996-04.
32. Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2010; 40:2969-75.
33. Frey B, Rubner Y, Kulzer L, Werthmöller N, Weiss EM, Fietkau R, Gaipl US. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother. 2014; 63:29-36.
34. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010; 107:4275-80.
35. Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 2013; 73:6900-12.
36. Peggs KS, Quezada SA, Chambers CA Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009; 206:1717-25.
37. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S. CTLA-4 control over FOXP3+ regulatory T cellfunction. Science. 2008; 322:271-75.
38. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO. 1992; 11:3887-95.
39. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. Exp Med. 2000; 192:1027-34.
40. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Med. 2002; 8:793-00.
41. Blank C, Brown I, Peterson Spiotto M, Iwai Y, Honjo T, Gajewski TF. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8 + T cells. Cancer Res. 2004; 64:1140-45.
42. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL. AJCC Cancer Staging Manual. (7th ed) Springer New York: 2010; XV, pp. 143-64.
43. Tanqri S, Vall H, Kaplan D, Hoffman B, Purvis N, Porwit A, Hunsberger B, Shankey TV. ICSH/ICCS Working Group. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS-part III-analytical issues. Cytometry B Clin Cytom. 2013; 84:291-308.